Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature

Abstract

Abstract Scleromyxedema is a rare and progressive disease that currently has no standard treatment. Triplet therapy with lenalidomide, bortezomib, and dexamethasone can be an effective therapy for scleromyxedema, especially in patients with refractory or relapsed disease.

Keywords

• bortezomib
• lenalidomide
• paraproteinemia
• plasma cells
• scleromyxedema
• treatment